New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
18:46 EDTPCYC, JNJImbruvica combination with anti CD20 antibody shows 'compelling' results
Pharmacyclics (PCYC) announced that IMBRUVICA, ibrutinib, in combination with the anti-CD20 antibody, ofatumumab, showed a Kaplan Meier estimate of continued clinical response at 18 months of 82.5% in heavily pre-treated patients with chronic lymphoma leukemia, CLL, small lymphocytic leukemia, SLL, prolymphocytic leukemia, PLL, and Richters Transformation, RT. The median duration of response for all dosing schedules in this study was not reached. The results from this study will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology,ASCO. This release corresponds to abstract 7009. IMBRUVICA is being jointly developed and commercialized by Pharmacyclics and Janssen Biotech (JNJ).
News For PCYC;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2015
12:17 EDTJNJMedivation plummets after Cowen highlights slowing Xtandi trends
Subscribe for More Information
11:23 EDTJNJMedivir says Janssen's Alios BIopharma starts Phase I AL-704 trial
Subscribe for More Information
July 28, 2015
07:05 EDTJNJMacroGenics reports MGD011 advances into clinical development
Subscribe for More Information
July 27, 2015
10:40 EDTJNJLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
July 23, 2015
17:51 EDTJNJJanssen submits sNDA to update label for Olysio
Subscribe for More Information
July 22, 2015
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use